C
CymaBay Therapeutics
Developing therapies for liver and other chronic diseases with high unmet medical need
About CymaBay Therapeutics
CymaBay Therapeutics is a biopharmaceutical company focused on developing innovative therapies to improve the lives of patients suffering from liver and other chronic diseases. The company operates primarily in the healthcare and pharmaceutical markets, targeting conditions such as primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH).
CymaBay's flagship product is seladelpar, a drug designed to treat PBC, a chronic liver disease. The company is also exploring the potential of seladelpar in combination with other drugs like liraglutide and selonsertib to treat fibrosis and NASH, a liver condition caused by fat buildup. These efforts are supported by extensive clinical trials and research, including collaborations with various medical professionals and institutions.
The primary clients of CymaBay are patients with liver diseases, healthcare providers, and medical institutions. The company aims to provide these clients with access to cutting-edge treatments that can significantly improve patient outcomes and quality of life.
CymaBay's business model revolves around the research, development, and commercialization of its pharmaceutical products. The company invests heavily in clinical trials to ensure the safety and efficacy of its drugs. Once a drug is approved by regulatory authorities, CymaBay generates revenue through sales to healthcare providers and institutions. Additionally, the company may enter into licensing agreements or partnerships with other pharmaceutical companies to expand the reach of its therapies.
In summary, CymaBay Therapeutics is dedicated to advancing medical treatments for liver and chronic diseases through innovative drug development. The company serves patients, healthcare providers, and medical institutions, operating within the healthcare and pharmaceutical markets. Its business model focuses on research, clinical trials, and commercialization to generate revenue.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 1988
- Headquarters
- Hayward, United States
- Listing
- IPO 2014
- Employees
- 24
- Open positions
- None listed
- Dealroom signal
- 28.2/100
- Industry
- Health
- Sub-industry
- Pharmaceutical
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITIONOther financing | Feb 2024 | — | $4.3B | Gilead Sciences | ↗ |
| POST IPO EQUITYOther financing | Sep 2023 | $150M | — | Undisclosed | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
| Year | Revenue | Growth | EBITDA | Margin |
|---|---|---|---|---|
| 2026 | $31M | 0% | −$86M | -275.9% |
| 2025 | $31M | 0% | −$86M | -275.9% |
| 2024 | $31M | 0% | −$86M | -275.9% |
| 2023 | $31M | +210.7% | −$86M | -275.9% |
| 2022 | $10M | 0% | −$91M | -910.9% |
| 2021 | $10M | 0% | −$87M | -867.3% |
| 2020 | $10M | — | −$53M | -533.8% |
Growth signals
Latest recorded traffic for CymaBay Therapeutics is 6.6K monthly website visits, up 88.6% over the last three months. CymaBay Therapeutics's team declined 76.5% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A7 investors entered at this stage
Alta Partners
KBC
Venrock
Birchmere Ventures
Novo Holdings- BCBay City Capital
Versant Ventures
Series B and later9 investors entered at this stage
Novo Ventures
Johnson & Johnson Development Corporation- MBMerlin Biomed
AllianceBernstein
VantagePoint Capital Partners- B(Biotech Turnaround Fund (BTF)
Silicon Valley Bank
Oxford Finance
Abingworth
Other known investors1 additional known investor
Gilead Sciences
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about CymaBay Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See CymaBay Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.